Neurocrine to acquire Soleno in $2.9bn transaction [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
The transaction will expand Neurocrine's portfolio in endocrinology and rare diseases via the addition of Soleno's lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR is a first-in-class therapy approved by the US Food and Drug Administration (FDA) for hyperphagia, the central symptom of the rare genetic disorder PWS. Following its US launch in the second quarter of 2025, the therapy generated revenues of $190m, with $92m in the fourth quarter alone for Soleno. Neurocrine's broader infrastructure is expected to increase Vykat XR's reach and efficacy. PWS is marked by behavioural, neurological, and metabolic dysfunctions, particularly hyperphagia. The acquisition will enable Neurocrine to offer three marketed first-in-class therapies: Ingrezza for tardive dyskinesia and Huntington's chorea, Crenessity for congenital adrenal hyperplasia, and Vykat XR for PWS. Intellectual property protections for Vykat XR are expected to last into the mid-204
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $204.00 to $242.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by Canaccord Genuity Group Inc. from $164.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by Wedbush from $151.00 to $166.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by HC Wainwright from $192.00 to $215.00. They now have a "buy" rating on the stock.MarketBeat
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 3
- NBIX's page on the SEC website